A ccording to the most recent data from the Centers for Disease Control and Prevention, 25.8 million people in the United States (8.3% of the population) have diabetes (1) . Type 2 diabetes accounts for 90-95% of diabetes diagnoses, and >85% of people with type 2 diabetes are overweight or obese (1) . Increased BMI, which is common in the type 2 diabetes population, has a well-established association with symptoms of gastroesophageal reflux disease (GERD) (2, 3) . Central adiposity is an important risk factor in the development of reflux and, subsequently, erosive esophagitis, Barrett's esophagus, esophageal adenocarcinoma, and gastric cardia adenocarcinoma (2, 3) .
Increased BMI is not the only risk factor for the development of GERD, particularly among people with diabetes. Among those with type 2 diabetes, peripheral neuropathy is an independent risk factor for erosive esophagitis (4) . In this population, there is a greater incidence of erosive esophagitis among individuals with neuropathy than among those without neuropathy, although those with and without neuropathy experience similar GERD symptoms (4) . Approximately 60-70% of people with diabetes have mild to severe forms of nervous system damage, which may partly explain why low-grade esophageal dysplasia is twice as likely in individuals with than in those without diabetes (1, 5) . Additionally, both asymptomatic and symptomatic reflux is more prevalent in individuals with diabetes than in those without diabetes (6, 7) . Likewise, type 2 diabetes has been demonstrated to be a risk factor for symptomatic GERD (8) .
Among individuals with diabetes, 40 .7% experience symptomatic GERD, and 70% of those use oral antidiabetic medications. Thus, it is likely that millions of individuals are managing blood glucose and GERD concomitantly with oral medications (1,7) Therefore, it is important to assess the drug interactions and clinical sequelae that may occur with this particular polypharmacy scenario. This article addresses the potential for vitamin B 12 depletion induced by concomitant use of metformin and acid-suppressing medications to contribute to neuropathy among individuals with diabetes.
Vitamin B 12 , Diabetes, and Neuropathy
Vitamin B 12 is a water-soluble micronutrient that serves as a cofactor for methionine synthase and L-methylmalonyl-CoA mutase (9-11). As a result, B 12 is important for the production of S-adenosylmethionine, nucleic acid methylation, and hemoglobin synthesis, as well as protein and fat metabolism (9, 11) . The signs and symptoms of vitamin B 12 deficiency can be easily mistaken for those of diabetic neuropathy. These include paresthesias, diminished vibratory sensation, diminished proprioception, loss of cutaneous sensation, muscle
weakness, abnormal reflexes, urinary and fecal incontinence, loss of vision, reduced sensory nerve conduction velocities, and axonal degeneration, as well as evoked potential and magnetic resonance imaging abnormalities consistent with demyelination (12-15).
Most individuals with diabetes have mild to severe forms of nervous system damage (1). B 12 supplementation, alone or in combination with other substances, has been demonstrated to improve multiple aspects of diabetic neuropathy, including lower-extremity epidermal nerve fiber density, cutaneous sensitivity, pain, paresthesia, autonomic symptoms, and ulnar motor and median sensory nerve conduction velocities (16-25).
Although These reports all noted improvement in diabetic neuropathy without also documenting baseline B 12 levels. Therefore, it is reasonable to assume that the neuropathy that responded to B 12 supplementation could have been, at least in part, B 12 deficiency neuropathy rather than diabetic neuropathy.
Metformin-Induced Vitamin B 12 Depletion
In 1969, Berchtold et al. (27) noted that patients managed with metformin therapy for 2-3 months malabsorbed vitamin B 12 . Since then, B 12 deficiency among individuals managed with metformin has been reported to occur at an incidence ranging between 5.6 and 36% (Table 1) (28-34). The broad range of incidence rates reported in Table 1 In general, acid suppressors including both histamine H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) have been documented to interfere with B 12 absorption (43) (44) (45) (46) (47) . In 1980, Steinberg et al. (48) found that, while undergoing treatment with H2RAs, patients were able to absorb unbound B 12 (i.e., B 12 from a vitamin supplement) but not protein-bound B 12 (i.e., B 12 from food sources). Numerous subsequent articles have also reported H2RA-induced B 12 depletion (49) (50) (51) . When protein-bound B 12 absorption was assessed before and after H2RA therapy, a 53% drop in absorption was noted (from 5.3% before treatment to 2.5% after treatment) (49) . When protein-bound B 12 absorption was assessed before and after ranitidine therapy, an 89% drop in absorption was noted (from 7.66% before treatment to 0.84% after treatment) (52). Other studies analyzing ranitidine have also noted decreases in B 12 (53) . In addition to H2RAs, studies have noted an inverse correlation between duration of PPI therapy and B 12 levels (54-57).
Mechanisms
Various reports have attributed acid suppressor-induced B 12 depletion to decreased gastric acid, pepsin, and intrinsic factor output (49, 50, 53, 58, 59 Figure 1 shows a schematic flowchart of the sequelae resulting from type 2 diabetes and GERD managed with metformin and acid-suppressing medications.
Discussion
Prevalence rates of both obesity and type 2 diabetes continue to increase over time (1, 61 
Regardless of the appropriateness of acid-suppressing medication use, in 2013 the acid-suppressing PPI esomeprazole was second in sales only to the antipsychotic aripiprazole (63). Given the increases in obesity and type 2 diabetes prevalence rates and the high consumption of PPIs, the potential exists for increasing concomitant use of antidiabetic and acid-suppressing medications.
Monotherapy with either metformin, an H2RA, or a PPI can deplete vitamin B 12 . In a recent study, 22.2% of individuals in a nondiabetic control group were found to be B 12 deficient, an incidence that did not differ statistically from that of the experimental groups of metformin users (21.9%) or PPI users (25.6%). However, a significant difference was found between control subjects and the 34.2% of concomitant users of metformin and PPI who were B 12 deficient (64) . This study supports the notion that concomitant therapy has an additive effect. Because metformin and acid-suppressing medications have been demonstrated to deplete B 12 independently and to have a compounded effect when used concomitantly, it is important to recognize the potential for neuropathy to develop as a result of this likely polypharmacy scenario.
Pharmacists, clinicians, and patients need to be aware of the potential for polypharmacy-induced B 12 depletion and the potential for subsequent neuropathy. Awareness is particularly important because metformin and acid-suppressing medications are commonly used in the diabetic population, which has a high prevalence of neuropathy (60-70%) (1) . Thus, what is generally thought of as "diabetic" neuropathy may be, at least in part, B 12 deficiency-induced neuropathy resulting from the concomitant use of these medications. Health care providers and people with diabetes also should be aware of the many strategies and alternatives that have been shown to improve B 12 deficiency and resultant neuropathy.
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